Frontline Pembrolizumab Regimens Receive Japanese Approval in Head and Neck Cancer

December 20, 2019 – Japan’s Pharmaceuticals and Medical Devices Agency has granted approval to frontline pembrolizumab as monotherapy and in combination with chemotherapy for the treatment of patients with recurrent or distant metastatic head and neck cancer. The approval for pembrolizumab in both indications is based on findings from the phase III KEYNOTE-048 trial, which evaluated the PD-1 inhibitor alone and in combination with platinum- … (leggi tutto)